Interferon alfa-2b
From Wikipedia, the free encyclopedia
|
Interferon alfa-2b
|
|
| Systematic (IUPAC) name | |
| N/A | |
| Identifiers | |
| CAS number | ? |
| ATC code | L03 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | Subcutaneous, intramuscular |
Interferon alfa-2b is an antiviral drug discovered and marketed by Schering-Plough under the tradename Intron-A. It has been used for a wide range of indications, including viral infections and cancers.
This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.
[edit] See also
[edit] External links
|
|||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
